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genomic hybridization (CGH) of more
than 200 tumors of the spectrum of
atypical spitzoid tumors in childhood,
including bona fide melanomas, and
have not observed copy number in-
creases at the KIT locus of chromosome
4 in a single case. Although the CGH
platform we used could have missed
focused aberrations, amplifications at the
KIT locus are typically readily obvious by
CGH (Bastian et al., 1998). In fact,
amplification of the KIT locus detected
by this method helped us discover KIT
mutations in acral and mucosal melano-
mas, as well as melanomas on chroni-
cally sun-damaged skin (Curtin et al.,
2006).
Finally, two of the three ‘‘low-
polysomy’’ and three of the four ‘‘KIT
gene alteration’’ cases that were also
analyzed for BRAF mutations in the
study also harbored BRAF V600E muta-
tions. In melanoma, KIT mutations and
copy number increases are highly
inversely correlated with mutations in
other oncogenes, including BRAF or
NRAS, further questioning a role for KIT
in this setting. After critical analysis of
the data presented, we thus see no
evidence to uphold the statement that
‘‘Cutaneous Melanoma in Childhood
and Adolescence Shows Frequent Gain
of KIT’’, as the title of this paper claims.
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TO THE EDITOR
We are pleased at the interest that Drs
Griewank and Bastian (2010) have
shown in our paper ‘‘Cutaneous Mela-
noma in Childhood and Adolescence
Shows Frequent Loss of INK4A and
Gain of KIT’’ (Daniotti et al., 2009). We
thank them for giving us this opportunity
to discuss our results in more detail,
because it was necessary to summarize
a large body of data in our published
work for the sake of brevity.
Melanoma is rare in pediatric
patients, and is often difficult to diag-
nose because of its atypical presentation
and histological uncertainty (Aldrink
et al., 2009; Ducharme and Silverberg,
2009; Jen et al., 2009; Kirkwood et al.,
2009; Mills and Messina, 2009). In our
institute, a total of about 50 melanoma
patients under 18 years of age have been
treated since 1975, compared with
approximately 800 new cases older than
18years treated each year. On the basis
of the incidence rates recorded by the
Italian Network of Cancer Registries, the
expected number of melanoma cases in
Italy is about 8 per year in children (age
0–14) and 15 per year in adolescents
(age 15–17) (Pastore et al., 2009).
Melanoma and the other solid malig-
nancies of childhood that have an
annual incidence of less than 2 per 1
million are included in a national-scale
cooperative project that is aimed at
improving clinical management and
research, through the development of
diagnostic and therapeutic recommen-
dations (Ferrari, 2009). In this context,
although only a few tissues were avail-
able for research studies, we decided to
proceed with the characterization of
somatic and germinal melanoma-asso-
ciated genetic alterations. To our knowl-
edge, this is the first study evaluating
pediatric lesions for abnormalities in
‘‘melanoma genes,’’ namely, BRAF,
NRAS, KIT, and CDKN2A, and the
patients for germline CDKN2A, CDK4
and MC1R genes.
Although the cases of pediatric
lesions analyzed are too few to allow
any statistical evaluation, the results are
indicative of genetic traits that only
partly overlap with those detected in
adult lesions, pointing to melanoma in
childhood as a suitable setting for
unraveling the novel genetic networks
in this tumor histotype.
In particular, the genetic analysis
carried out showed that pediatric
melanoma lesions show (i) the most
frequent adult melanoma gene muta-
tion activating the BRAF oncogene,
thus representing actual candidates
for therapy with specific targeted
agents; (ii) frequent loss of the CDKN2A
gene, corroborating the existence of
molecular pathogenetic mechanisms
in common with adult melanoma; and
(iii) frequent KIT alterations, which
appear to be a peculiarity of childhood
lesions.
In addition, the analysis of known
melanoma susceptibility genes revealed
a peculiar pattern, evidenced by the
comparison with series of familial
melanoma cases studied in parallel. In
fact, the lack of CDKN2A germline
mutations in the absence of a melanoma
family history was observed. Moreover,
www.jidonline.org 2331
M Rodolfo et al.
Response to Griewank and Bastian
the frequency of MC1R variants was
similar to that in the normal population
and lower than that detected in familial
cases, suggesting a prevalent role for
other pigmentation-related genes.
Griewank and Bastian argue that the
results presented in our study do not
support the conclusion of an involve-
ment of the KIT gene as described in the
article’s title. They raise a series of
points denoting a possible lack of
clarity in the data we reported; we
address each comment in detail below.
The mutation analysis of KIT re-
vealed three mutations—two silent
and one intronic—in exon 9 and intron
17. Obviously, mutations were defined
as somatic because they were unde-
tectable in the patients’ normal tissues,
with two of them also lacking in a
second tumor biopsy from the same
patients (as shown in Supplementary
Table S2 online of the article). Silent
gene sequence alterations do not alter
the amino acid sequence of the en-
coded protein, although they seem to
have potential in the regulation of gene
expression.
The frequency of the rs3733542 KIT
polymorphism (depicted in Supplemen-
tary Figure S1 of the article) appears to
be similar in the studied patients (1/7
pediatric, homozygous, and 1/8 famil-
ial, heterozygous; G allele frequency
10%), as well as in the healthy
European population (9%).
KIT copy number, evaluated by
fluorescent in situ hybridization using
as a probe the BAC clone RP11-586A2
labeled with green along with the
orange-labeled CEP4 control probe, as
by Miselli et al. (2007), revealed a ‘‘low
polysomy’’ state in 4/8 pediatric mela-
noma cases (compared with 1/7 famil-
ial melanomas). Given that ‘‘low
polysomy’’ is defined as a condition in
which three or four CEP4 signals are
associated with the same number of
gene signals ino40% of cells, it can be
concluded that the cells have three or
four copies of chromosome 4. One
example is given in Figure 1 in the
article. Because the samples are diploid
or monosomic for chromosome 9, they
are probably not polyploid.
The apparent discrepancy in KIT
copy number increase found in our
study (due to the increase in chromo-
some 4 copy number as explained
above), and the lack of a specific KIT
copy number increase in the CGH
analysis by Dr Bastian’s group in more
than 200 spitzoid tumors in childhood,
may be due to the fact that none of the
lesions in our little series was a spitzoid
tumor or a metastatic deposit of a
spitzoid melanoma (as detailed in the
article’s Supplementary Table S1).
Finally, V600EBRAF mutation was
detected in two lesions showing low
polysomy of KIT, of which one had a
silent mutation. Although KIT muta-
tions/amplifications are mutually exclu-
sive with BRAF and NRAS mutations,
only a few exceptions have been
reported—by Curtin et al. (2006) and
Ashida et al. (2009). In our study, a
primary melanoma from a familial case
was shown to carry the V600E BRAF
and a concomitant—and to our knowl-
edge previously unreported—S864F
KIT activating mutation.
In conclusion, we entirely agree that
our data do not support any indication
to treat pediatric melanoma with im-
atinib or other KIT inhibitors, and
indeed no proposal of this sort was
made in the article. Nevertheless,
the relative rate of KIT abnormalities
suggests that analysis of this gene
should be incorporated in research
studies on pediatric melanoma. From
a clinical viewpoint, however, there is
no doubt that these tumors are candi-
dates for therapy with V600EBRAF-
specific small molecules currently
under clinical testing.
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SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
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